
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 30
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT01975831 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | ||
NCT02963831 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | ||
NCT04787991 | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | ||
NCT03435380 | Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer | ||
NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 | ||
NCT05701657 | Nutrition for Precision Health, Powered by the All of Us | ||
NCT02336165 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | ||
NCT03214250 | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | ||
NCT04426201 | InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) | ||
NCT04093167 | Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC | ||
NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | ||
NCT02898116 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | ||
NCT00124124 | Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine | ||
NCT04918186 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | ||
NCT01079741 | Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | ||
NCT01239134 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | ||
NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | ||
NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | ||
NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | ||
NCT03461952 | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | ||
NCT02822703 | Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation | ||
NCT00821652 | Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination | ||
NCT03000751 | CT DOSE Collaboratory | ||
NCT03651271 | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | ||
NCT01636388 | Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma | ||
NCT03835533 | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations | ||
NCT00142454 | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | ||
NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant | ||
NCT02057445 | 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma | ||
NCT05084833 | ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study |